Twilight, the Dawn of a New Era of Aspirin-Free PCI?

Patrick W. Serruys; Kuniaki Takahashi; Ply Chichareon; Yoshinobu Onuma

doi:10.1016/j.jacc.2020.03.071

Related publications

Article2009

First case of stenting of a vulnerable plaque in the SECRITT I trial—the dawn of a new era?

Steve Ramcharitar, Nieves Gonzalo, Robert‐Jan van Geuns, Héctor M. García‐García, Joanna J. Wykrzykowska, Jürgen Ligthart, Evelyn Regar, Patrick W. Serruys

Nature Reviews Cardiology

Article2020

Aspirin-free antiplatelet regimens after PCI: when is it best to stop aspirin and who could ultimately benefit?

Mariusz Tomaniak, Robert F. Storey, Patrick W. Serruys

EuroIntervention

Letter2021

Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?

Mattia Lunardi, Yoshinobu Onuma, Patrick W. Serruys

European Heart Journal

Article2024

TCT-231 Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

Kotaro Miyashita, Takashi Muramatsu, Gaku Nakazawa, Yuki Ishibashi, Yoshinobu Onuma, Pedro A. Lemos, Patrick W. Serruys

Journal of the American College of Cardiology

Editorial Material2015

The era of a new generation of interventionalists: a hybrid of a surgeon and an interventionalist?

Patrick W. Serruys